上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
Fosfomycin tromethamine (Synonyms: 磷霉素氨丁三醇; MK-0955 tromethamine)
Fosfomycin (MK-0955) tromethamine 是一种能透过血脑屏障的广谱抗生素，不可逆地抑制细胞壁合成的早期阶段。Fosfomycin tromethamine 对多种细菌具有杀菌活性，这些细菌包括耐多药 (MDR)，广泛耐药 (XDR) 和耐全药 (PDR) 细菌。
Fosfomycin tromethamine Chemical Structure
CAS No. : 78964-85-9
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
Fosfomycin tromethamine 的其他形式现货产品:
Fosfomycin calcium Fosfomycin sodium
| 生物活性 |
Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].
|
体外研究
(In Vitro) |
Fosfomycin tromethamine is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis[1].
Fosfomycin tromethamine has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%[1].
Fosfomycin tromethamine displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses[2].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
|
体内研究
(In Vivo) |
Fosfomycin tromethamine (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats[3].
Pharmacokinetic of Fosfomycin Tromethamine in Rats[4]
| Dibekacin Dose (mg) |
Vdss (l/kg) |
β (min-1) |
T1/2 (min) |
Urinary recovery (%) |
| 30 |
0.261 |
0.0244 |
28.4 |
85 |
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Fischer 344 rats[3] |
| Dosage: |
320 mg/kg |
| Administration: |
Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days |
| Result: |
Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment. |
| Animal Model: |
Dehydrated Wistar rat with acute renal failure (8-week-old)[4] |
| Dosage: |
120 mg/kg |
| Administration: |
Intravenous injection; once |
| Result: |
Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin. |
|
| Clinical Trial |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 中文名称 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
-
[1]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24.
[2]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47.
[3]. Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69.
[4]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
